Immuneering Corp

Deep Cyclic Inhibition

DCI platform leveraging translational bioinformatics and 3D tumor modeling to design small molecule Deep Cyclic Inhibitors targeting core cancer signaling pathways including MAPK (RAS/RAF/MEK/ERK) and other oncogenic pathways, with focus on solid tumor oncology.

Targets: MEK, ERK, MAPK pathway

Disease Cancelling Technology

DCT is a computational target identification platform using human transcriptomic data to identify novel drug targets and new ways to modulate existing targets for oncology drug discovery; disease-agnostic but currently focused on oncology.